Cerivastatin drug data and news

---

Bayer gets subpoena regarding withdrawn cholesterol drug  06 Mar 2006
AP) _ Bayer AG disclosed Monday that it received a subpoena from the US attorney for New Jersey relating to its withdrawn Baycol/Cerivastatin anti-cholesterol ... - Newsday,

Statins in coronary artery disease  Jan 28, 2006
This family of statins has seven members. They are lovastatin, fluvastatin, pravastatin, simvastatin, rosuvastatin, atorvastatin and cerivastatin. ... - Malaysia Star,

Studies: Statins Don't Cut Risk of Colon, Other Cancers  Jan 9, 2006
The specific statins studied included atorvastatin (Lipitor, Caduet), cerivastatin (Baycol), fluvastatin (Lescol), lovastatin (Advicor, Altoprev, Mevacor ... - ACS News Center,

Former FDA Commissioner’s Ownership of Stock in Regulated ...  Oct 30, 2005
Duragesic Patch (fentanyl transdermal patch) – 2004; Ephedra – 2004 (withdrawal order vacated by a federal judge); Baycol (cerivastatin) – 2001; Raplon ... - Newsinferno.com,

'Drug industry is as good or as bad as the regulators'  Oct 12, 2005
...etc. Recent drug withdrawals include terfenadine, mibefradil, cerivastatin, troglitazone, Rofecoxib and Vioxx, just to name a few. ... - Jakarta Post,

Omega-3 fatty acids better than statins in reducing death  Aug 11, 2005
A seventh statin, cerivastatin (Baycol) was removed from the market in 2001 because of potentially serious side effects and a number of deaths. ... - Health Sentinel

Maker of Crestor revises warning label for its controversial ...  Aug 1, 2005
Currently, the risk of Rhabdomyolysis from Crestor is very similar to another cholesterol-lowering medication, Baycol (cerivastatin) which was completely ... - PR Leap (press release)

Drugs Banned worldwide still available in India  Jul 11, 2005
Some of the names of the drugs banned in other parts of the world but available in India include anagen, cerivastatin, droperidol, furazolidone, lynestrenol ... - MedIndia <**results**>

Drugs Banned worldwide still available in India  11 Jul 2005
Some of the names of the drugs banned in other parts of the world but available in India include anagen, cerivastatin, droperidol, furazolidone, lynestrenol ... - MedIndia

Let's Protect Others from Life-threatening Diseases  Jun 17, 2005
...drugs from the United States market. Baycol (cerivastatin) is administered to manage cholesterol. It was later discovered that this ... - AllAfrica.com,

Let's Protect Others from Life-threatening Diseases  Jun 17, 2005
...drugs from the United States market. Baycol (cerivastatin) is administered to manage cholesterol. It was later discovered that this ... - AllAfrica.com,

New Review Article Published in The Digest Of Urban Cardiology ...  Apr 29, 2005
Lipitor(R)), simvastatin (Zocor(R)), pravastatin (Pravachol(R)), fluvastatin (Lescol(R)), lovastatin (Mevacor(R)) and the now withdrawn cerivastatin (Baycol(R ... - PR Newswire

New Review Article Published in The Digest Of Urban Cardiology ...  Apr 29, 2005
Lipitor®), simvastatin (Zocor®), pravastatin (Pravachol®), fluvastatin (Lescol®), lovastatin (Mevacor®) and the now withdrawn cerivastatin (Baycol®). ... - Yahoo News

The statin war  Apr 22, 2005
Rosuvastatin was the new statin approved in 2003 after the withdrawal of Bayer’s cerivastatin in 2001. The drug has been under ... - Express Pharma Pulse

Arthritis Medications and Cardiovascular Events  Apr 26, 2005
Likewise, although cerivastatin was removed from European and US markets in August 2001 because of a high risk of rhabdomyolysis, 5 other statins continue to ... - Journal of American Medical Association (subscription)

Five Statins Equally Effective in Secondary MI Prevention  Apr 28, 2005
These were Crestor (rosuvastatin), which was not available when cohort enrollment began in April 1997; and Baycol (cerivastatin), which was withdrawn from the ... - MedPage Today,

Five Statins Equally Effective in Secondary MI Prevention  28 Apr 2005
These were Crestor (rosuvastatin), which was not available when cohort enrollment began in April 1997; and Baycol (cerivastatin), which was withdrawn from the ... - MedPage Today

Arthritis Medications and Cardiovascular Events  Apr 26, 2005
Likewise, although cerivastatin was removed from European and US markets in August 2001 because of a high risk of rhabdomyolysis, 5 other statins continue to ... - Journal of American Medical Association (subscription)

Public Citizen: Statin-Associated Rhabdomyolysis  Apr 6, 2005
Non-cerivastatin cases had a median peak CPK value of 15 080 IU/L with 38% of cases having peak CPK values ?10 000 IU/L (the cut-off used by Chang), while the ... - PharmaLive.com

The statin war  Apr 22, 2005
Rosuvastatin was the new statin approved in 2003 after the withdrawal of Bayer’s cerivastatin in 2001. The drug has been under ... - Express Pharma Pulse,

Letter to FDA Proving That Crestor Has Higher Rates of ...  Mar 10, 2005
...the FDA waited for a deadly, patient-damaging year between its realization of an increased rate of rhabdomyolysis reports for Baycol (cerivastatin) compared to ... - PharmaLive.com (press release),

World pharma markets still slowing down  Mar 10, 2005
...has claimed some high profile casualties including big-selling medications such as Merck & Co’s Vioxx (rofecoxib) and Bayer’s Lipobay/Baycol (cerivastatin ... - Drug Researcher.com,

Congressional Testimony by Sidney Wolfe MD on Current Issues ...  Feb 11, 2005
Baycol (cerivastatin-cholesterol lowering) Approximately one year before Baycol was removed from the market in August 2001, its manufacturer Bayer, using FDA ... - PharmaLive.com (press release),

Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals:

Skeletal Muscle.

ANTACID (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of antacid.

CIMETlDINE: Cerivastatin plasma concentrations were not affected by co-administration of cimetidine.

CHOLESTYRAMINE: The influence of the bile-acidsequestering agent cholestyramine on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies. In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for C_max when compared to dosing cerivastatin sodium alone. However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in C_max of about 30% when compared to dosing cerivastatin sodium alone. Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.

DIGOXIN: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium. Cerivastatin plasma concentrations were also not affected by co-administration of digoxin.

WARFARIN: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo. The AUC and C_max of both the (R) and (S) isomers of warfarin were unaffected by concurrent dosing of 0.3 mg cerivastatin sodium. Co-administration of warfarin and cerivastatin did not alter the pharmacokinetics of cerivastatin sodium.

ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.

OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.